Clinical Trial Pipeline Robust and Promising
According to a new research report by RNCOS entitled, “US Non-Invasive Prenatal Diagnostics – Market Insight”, the research pipeline for NIPD tests is robust and will help to reveal new avenues. Several Non-invasive Aneuploidy-based studies have been taking place with the primary aim to identify new biomarkers from the pregnant mother without invading the fetus. The research pipeline is being led by companies already in the NIPD business and these companies are trying to carry validation studies for existing products and also lead to new discoveries. Validation studies are majorly being conducted to evaluate the utility of the advanced tests in pregnancies with varying risk of aneuploidies. Amongst the major focus areas are Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations and other Microdeletions.
